The global Epigenetics Market was valued at USD 754.97 million in 2016 and is projected to reach USD 2286.09 million by 2025, growing at a CAGR of 13.1% from 2017 to 2025.
Epigenetics is a genetic phenomenon which involves a significant change in the genetic make-up of an organism due to surroundings and adaptive factors. Evolution and developmental studies contain thorough studies about epigenetic factors and changes. Current pharmaceutical discoveries aim at developing the drugs suitable for present environmental factors and thus end up investing in the epigenetic research and methodologies causing market to expand at a rapid pace.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Sequencing is becoming economically favorable
1.2 Growing interest in genetic studies and increased funds from Govt. and Private sector both
1.3 Growing Cases of Cancer Patients all over the Globe
2. Market Restraints
2.1 High Cost of instruments and equipment
Market Segmentation:
1. Global Epigenetics Market, by Application:
1.1 Oncology
1.2 Metabolic Diseases
1.3 Developmental Biology
1.4 Immunology
1.5 Cardiovascular Diseases
1.6 Other Applications
2. Global Epigenetics Market, by End User:
2.1 Academic and Research Institutes
2.2 Pharmaceutical and Biotechnology Companies
2.3 Contract Research Organizations
3. Global Epigenetics Market, by Technology:
3.1 DNA Methylation
3.2 Histone Modification
3.3 Other Technologies
4. Global Epigenetics Market, By Products:
4.1 Kits
4.1.1 Chip-Seq Kits
4.1.2 Bisulfite Conversion Kits
4.1.3 Whole-Genome Amplification Kits
4.1.4 5-HMC and 5-MC Analysis Kits
4.1.5 RNA Sequencing Kits
4.1.6 Other Epigenetics Kits
4.2 Reagents
4.2.1 Antibodies
4.2.2 Magnetic Beads
4.2.3 Histones
4.2.4 Buffers
4.2.5 Primers
4.2.6 Other Epigenetics Reagents
4.3 Enzymes
4.3.1 DNA-Modifying Enzymes
4.3.2 Protein-Modifying Enzymes
4.3.3 RNA-Modifying Enzymes
4.4 Instruments and Consumables
4.4.1 Next-Generation Sequencers
4.4.2 Qpcr Instruments
4.4.3 Mass Spectrometers
4.4.4 Sonicators
4.4.5 Other Instruments and Consumables
4.5 Bioinformatics Tools
5. Global Epigenetics Market, by Region:
5.1 North America (U.S., Canada, Mexico)
5.2 Europe (Germany, UK, France, Rest of Europe)
5.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
5.4 Latin America (Brazil, Argentina, Rest of Latin America)
5.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. Illumina
2. Thermo Fisher Scientific
3. Merck Millipore
4. Abcam
5. Active Motif
6. Bio-Rad
7. New England Biolabs
8. Agilent
9. Qiagen
10. Zymo Research
11. Perkinelmer
12. Diagenode
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Epigenetics Market was performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL EPIGENETICS MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL EPIGENETICS MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL EPIGENETICS MARKET, BY APPLICATION
5.1 Overview
5.2 Oncology
5.3 Metabolic Diseases
5.4 Developmental Biology
5.5 Immunology
5.6 Cardiovascular Diseases
5.7 Other Applications
6 GLOBAL EPIGENETICS MARKET, BY END USER
6.1 Overview
6.2 Academic and Research Institutes
6.3 Pharmaceutical and Biotechnology Companies
6.4 Contract Research Organizations
7 GLOBAL EPIGENETICS MARKET, BY TECHNOLOGY
7.1 Overview
7.2 DNA Methylation
7.3 Histone Modification
7.4 Other Technologies
8 GLOBAL EPIGENETICS MARKET, BY PRODUCT
8.1 Overview
8.2 Kits
8.2.1 Chip-Seq Kits
8.2.2 Bisulfite Conversion Kits
8.2.3 Whole-Genome Amplification Kits
8.2.4 5-HMC and 5-MC Analysis Kits
8.2.5 RNA Sequencing Kits
8.2.6 Other Epigenetics Kits
8.3 Reagents
8.3.1 Antibodies
8.3.2 Magnetic Beads
8.3.3 Histones
8.3.4 Buffers
8.3.5 Primers
8.3.6 Other Epigenetics Reagents
8.4 Enzymes
8.4.1 DNA-Modifying Enzymes
8.4.2 Protein-Modifying Enzymes
8.4.3 RNA-Modifying Enzymes
8.5 Instruments and Consumables
8.5.1 Next-Generation Sequencers
8.5.2 Qpcr Instruments
8.5.3 Mass Spectrometers
8.5.4 Sonicators
8.5.5 Other Instruments and Consumables
8.6 Bioinformatics Tools
9 GLOBAL EPIGENETICS MARKET, BY GEOGRAPHY
9.1 Overview
9.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the World Regional Market Estimates and Forecasts, 2012 â€" 2025
10 GLOBAL EPIGENETICS MARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies
11 COMPANY PROFILES
11.1 Illumina
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments
11.2 Thermo Fisher Scientific
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments
11.3 Merck Millipore
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments
11.4 Abcam
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments
11.5 Active Motif
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments
11.6 Bio-Rad
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments
11.7 New England Biolabs
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments
11.8 Agilent
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments
11.9 Qiagen
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Developments
11.10 Zymo Research
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Developments
11.11 Perkinelmer
11.11.1 Overview
11.11.2 Financial Performance
11.11.3 Product Outlook
11.11.4 Key Developments
11.12 Diagenode
11.12.1 Overview
11.12.2 Financial Performance
11.12.3 Product Outlook
11.12.4 Key Developments
12 Appendix
12.1 Related Reports